Skip to content
Companies

Infinity Bio

Antibody profiling against large antigen libraries

Raised to date

$2M

of $5M offered across 1 Form D filing

Still open
$3M
Investors
2
Last filed
Mar 11, 2025

About

Infinity Bio, Inc. is an innovative biotechnology company focused on providing advanced antibody profiling services. Established in 2023 and headquartered in Baltimore, Maryland, the company utilizes cutting-edge technology developed at Johns Hopkins University to address the complexities of antibody responses within the immune system.

Infinity Bio stands out by offering proprietary MIPSA technology, enabling detailed and comprehensive analyses of antibody reactivity across extensive antigen libraries.

Funding

  • DebtFiled Mar 11, 2025Form D
    $2M/ $5M

Product

MIPSA (Molecular Indexing of Proteins by Self-Assembly)

Antibody Profiling Technology

MIPSA is Infinity Bio's proprietary technology designed for the intricate mapping of antibody reactivity against large libraries of antigens. This innovative platform allows for comprehensive profiling of antibodies, facilitating a deeper understanding of immune responses.

  • Detailed antibody reactome profiling
  • Capability to analyze large antigen libraries
  • High-throughput analysis support

Built for

Biomedical research and pharmaceutical industries

People on file